JGC
SRPT icon

J. Goldman & Co’s Sarepta Therapeutics SRPT Stock Holding History

J. Goldman & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87,866
Closed -$9.25M – 620
2024
Q4 		$10.7M Sell
87,866
-11,372
-11% -$1.39M 0.28% 106
2024
Q3 		$12.4M Buy
99,238
+55,585
+127% +$7.68M 0.35% 88
2024
Q2 		$6.9M Buy
+43,653
New +$5.61M 0.2% 142
2023
Q3 		– Sell
-1,775
Closed -$203K – 474
2023
Q2 		$203K Buy
+1,775
New +$229K 0.01% 327
2019
Q4 		– Sell
-70,947
Closed -$5.34M – 349
2019
Q3 		$5.34M Buy
+70,947
New +$8.38M 0.4% 82
2018
Q2 		– Sell
-43,767
Closed -$4.13M – 454
2018
Q1 		$3.24M Sell
43,767
-23,124
-35% -$1.54M 0.14% 171
2017
Q4 		$3.72M Sell
66,891
-37,632
-36% -$1.99M 0.2% 136
2017
Q3 		$4.74M Buy
104,523
+70,423
+207% +$2.81M 0.24% 119
2017
Q2 		$1.15M Buy
34,100
+25,600
+301% +$834K 0.06% 206
2017
Q1 		$252K Sell
8,500
-91,400
-91% -$2.83M 0.01% 296
2016
Q4 		$2.74M Buy
99,900
+95,525
+2,183% +$3.84M 0.18% 151
2016
Q3 		$269K Sell
4,375
-85,800
-95% -$2.59M 0.02% 278
2016
Q2 		$1.72M Buy
+90,175
New +$1.67M 0.09% 212
2015
Q4 		– Sell
-1,813
Closed -$58K – 298
2015
Q3 		$58K Buy
+1,813
New +$61.5K 0.01% 199

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's SRPT Position: Q1 2025 in Review

J. Goldman & Co sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 87,866 shares — an estimated $9.25M sold.

J. Goldman & Co first reported a position in SRPT in Q3 2015 and held it in 14 quarters. The position peaked at $12.4M in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • J. Goldman & Co reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • J. Goldman & Co sold 87,866 Sarepta Therapeutics shares in Q1 2025, an estimated $9.25M.
  • J. Goldman & Co first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 14 quarters.
  • J. Goldman & Co's Sarepta Therapeutics position peaked at $12.4M in Q3 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.